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Lyerly et al refer to historical aspects of the rubella vaccination program as “a cautionary 
tale about caution” concerning Zika vaccine research.1 The US rubella vaccination program 
has been a tale of appropriate caution and a remarkable success in rubella and congenital 
rubella syndrome (CRS) elimination2. We concur with the authors' assertion that safety 
studies in pregnant women are important and could have overcome the initial reluctance to 
give rubella vaccine to women of childbearing age (WCBA). However, points within the 
article warrant comment.
First, Lyerly suggests that the limited evidence that receipt of vaccine during pregnancy did 
not cause fetal harm when the US rubella vaccination program began in 1969 should have 
led to recommendations regarding vaccination of WCBA in the first decade of the vaccine 
use. Wild rubella virus was a known teratogen, and in 1969, it was known that rubella 
vaccine virus crossed the placenta3. The vaccine virus's teratogenic potential was not known. 
If the vaccine virus caused birth defects, and the focus for vaccination was WCBA, 
thousands of women unknowingly pregnant at the time of vaccination, especially in the first 
trimester, could have been at high risk of a newborn with birth defects. Over time, as 
evidence showed no risk to the fetus, recommendations regarding vaccination of non-
pregnant WCBA were strengthened4.
Secondly, Lyerly contends that the initial rubella immunization strategy was historically 
“ineffective” in reaching its goals. We contend that the initial goal of the program --- to 
protect WCBA by reducing exposure to disease2 --- was appropriately cautious and 
effective, given the absence of data on risks of rubella vaccine in pregnancy and the recent 
memories of the thalidomide tragedy. By focusing the vaccination strategy on infants up to 
pre-pubertal children, where most disease occurred, the goal was to markedly reduce rubella 
transmission within the first few years and to reduce the burden of CRS over time, because 
fewer susceptible pregnant females would be exposed to wild virus.
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Finally, most of the vaccine candidates for Zika prevention are not live attenuated whole 
Zika viruses5. In contrast, rubella vaccines licensed in 1969 were live attenuated viruses that 
could have been teratogenic. Thus, some concerns about rubella may not apply to current 
vaccine candidates to prevent Zika infection. Nevertheless, the rubella experience highlights 
the importance of collecting vaccine safety data post-licensure when vaccination of pregnant 
women takes place, because women are vaccinated who are unknowingly pregnant.
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